Cristian Vilos, PhD
School of Medicine
Universidad de Talca
Dr. Cristian Vilos is the principal investigator of the Laboratory of Nanomedicine Targeted Delivery at the School of Medicine of the University of Talca. Dr. Vilos is focused on the development of advanced nanotherapeutics based on polymeric nanoparticles for the intracellular release of macromolecules, improvements in poorly water-soluble drugs, the co-liberation of therapeutic agents, and the advancement of therapies based on targeted delivery of drugs to particular cells or tissues. The foundations of his investigation involve several fields related to the pipeline of "drug development," including the study of nano-bio interactions, self-assembled nanostructures, advanced materials including co-polymers, and stimuli-responsive biopolymers, and drug delivery based on nanopharmacology. All of the above, including the mechanisms involved with the fundamental biology, physiology, nanotoxicology, and nanosafety.
Dr. Vilos majored in Medical Technology at the University of Talca and later received his Ph.D. in Biotechnology at the University of Santiago in Chile. From 2013 to 2015, Dr. Vilos was a Visiting Professor and a Postdoctoral Fellow at the Laboratory of Nanomedicine and Biomaterials at Department of Anesthesia at Brigham and Women's Hospital and Harvard Medical School (HMS) mentored by Professor Omid Farokhzad. Also, Dr. Vilos was a member of the Langer Lab at David H. Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology. Dr. Vilos was a principal investigator of the Faculty of Medicine of Andres Bello University (2012-2018) and was awarded for his outstanding scientific career as a young researcher.
Currently, Dr. Vilos lead the Line-6 of Nanobiomedicine at the Basal Center for the Development of Nanoscience and Nanotechnology (CEDENNA) supported by the National Commission for Scientific and Technological Research (CONICYT) of the Government of Chile. The leading projects under development in his laboratory are centered on colorectal cancer. He hypothesizes that combined therapy based on p38α MAPK inhibitor (skepinone-L) with the chemotherapeutic drugs (5–FU, irinotecan, or cisplatin) encapsulated in targeted nanoparticles induce a mechanistic synergism on the cellular death of sensitive and resistant colorectal cancer (Fondecyt Regular). Other projects in progress include the development of nanotherapies based MAPK and MEK/ERK inhibitors for colorectal cancer (Fondecyt-Postdoc) and the study of synergism of combined therapy based on mTOR inhibitor and cytotoxic agents for colorectal cancer. Also, Dr. Vilos is running a handful of projects related to chronic pain, migration of neutrophil, antiplatelet effects, bone regeneration, and targeted ligand development.
Dr. Vilos group includes one Postdoc, and three Ph.D. students from UNAB, USACH, and UFRO. Currently, his lab is supported by a Postdoctoral Fondecyt (2017-2019), a Basal Grant Center (CEDENNA) (2015 - 2022), the European Union's Horizon 2020 Research and Innovation Program under the Marie Sklodowska-Curie Grant Agreement #734801 (2017 - 2021).
Prof. Vilos has a tremendous international network of collaboration with great investigators and friends from Harvard Medical School, the DTU Nanotech at the Technical University of Denmark, the Imperial College of London, the Korean Institute of Ceramic Engineering and Technology, the Bioengineering Department of George Mason University, and from the Department of Chemistry & Chemical Engineering of LUMS University of Pakistan. In Chile, He works actively with a selected group of collaborators from Universidad de Talca, The Universidad del Desarrollo, Universidad de Santiago, Universidad Andrés Bello, and the Pontificia Universidad Católica de Chile in the development of different projects.
In summary, Dr. Vilos investigate nanomedicine and targeted delivery of drugs centered in the formulations, the nano-bio interactions, and the evaluation in vitro and in vivo of nanoparticles as therapeutic strategies.
Bruno A. Cisterna, MSc., PhD
Lab of Nanomedicine Targeted Delivery
Nitin Bharat Charbe, PhD
Lab of Nanomedicine Targeted Delivery (UNAB)
Lab of Design and Organic Synthesis (PUC)
Co-mentoring with Prof. Flavia Zacconi at PUC.
Juan Pablo García
PhD Student in Biotechnology
University of Santiago of Chile
Co-mentoring with Prof. Carmen Gloria Feijoo from UNAB.
PhD Student in Biotechnology
Andres Bello University
Co-mentoring with Prof. Flavia Zacconi from PUC.
María Francisca Uribe
PhD Student in Medical Sciences
University La Frontera
Camilo Figueroa, Undergraduate Student in Biotechnology, Universidad Andres Bello (2019).
María Francisca Matus, PhD in Science, I+D Bioactive Products, University of Talca (2018).
Daniela Olea, Undergraduate Student in Medical Technology, Universidad Andres Bello (2016).
Consuelo Rivera, Undergraduate Student in Medical Technology, Universidad Andres Bello (2016).
Cristian Espinoza, Undergraduate Student in Medical Technology, Universidad Andres Bello (2016 ).
Soung-Jae Bong, Undergraduate Student in Chemical Engineering, University of Waterloo, Canada (2015).
Daniela Bahamonde, Undergraduate Student in Medical Technology, Universidad Andres Bello (2015).
Álvaro Molina, Undergraduate Student in Medical Technology, Universidad Andres Bello (2015).
Training and Visit of Research
Guillermo Gamboa, PhD Student in Biomedical Sciences, University of Talca. 2019 (seven months).
Irene Romayor Arredondo, PhD Student at Department of Cell Biology and Histology, Faculty of Medicine and Nursing, University of País Vasco UPV/EHU, Spain. 2019 (four months).
Alba Herrero Alonso, PhD Student at Department of Cell Biology and Histology, Faculty of Medicine and Nursing, University of País Vasco UPV/EHU, Spain. 2019 (four months).
Irene Aizpitarte Morán, PhD Student at University of País Vasco UPV/EHU, Spain. 2018 (one month).